Navigation Links
Aquavit Pharmaceuticals Adds New Advanced Drug Delivery Technology to Product Portfolio
Date:11/5/2013

NEW YORK, Nov. 5, 2013 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. has further extended its personalized drug delivery platform by signing a binding preliminary agreement with Huons Co, Ltd. (KOSDAQ: 84110), a leading Korean pharmaceuticals company. The agreement formalizes the strategic partnership between the parties and gives Aquavit the worldwide, perpetual, and unlimited license for global commercialization of a cutting-edge drug-delivery system.

The two companies will be investing up to 20 Million USD to further develop the technology and bring to market the highest standard, GMP manufactured product innovations.

"It is a very exciting technology extension for Aquavit. I can already think of many applications and possibilities," said Dr. Nark K. Roh, a world renowned dermatologist and Medical Director of Leaders Clinic.

Aquavit's integrated platform includes innovative microneedle technology, first-of-its-kind desktop robotics for real-time formulations, and proprietary and personalized compounds and admixtures tied together by an advanced health informatics technology. Recently, Aquavit showcased its platform technology at the Big Data in Pharma Conference (Big Dip 2013) opening the Big Data Applications Session.

Earlier this year, Aquavit in-licensed its first microneedle delivery system, AQT-001 branded as AQUAGOLD® fine touch™. Aquavit holds the perpetual, exclusive, worldwide right to license, sub-license, improve and/or commercialize the AQT series and all derivative intellectual property. The AQT series has FDA, CE Mark and KFDA registration and will commerce global distribution in early 2014.

"We look forward to unveiling this latest technology to the public at the 72nd American Academy of Dermatology Annual Meeting in Denver in March, 2014. We aim to be a leader in personalized treatment options integrating cutting-edge technology, assessment tools, and knowledge of our key opinion leaders," said Sobin Chang, CEO of Aquavit.

About Huons Co., Ltd.
Huons Co, Ltd. (KOSDAQ: 84110) is a leading Korean pharmaceuticals company focusing in the development and distribution of drugs, medical devices and regulated cosmetics. It's areas of strength are Urology Orthopedic Surgery, Anti-Arthritis, Anesthetics, Natural Well-Being Products including Anti-Obesity, Gynecology and related Women's Health and Dental Care. For more information, visit www.huons.com.   

About Aquavit Pharmaceuticals, Inc.
Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical device, and health technologies adapted for the new personalized health paradigm. For more information, visit www.aquavitpharma.com.


'/>"/>
SOURCE Aquavit Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aquavit Pharmaceuticals and U-Bio Med Enter Exclusive Worldwide License Agreement for Microneedle Technology (AQT-001)
2. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
3. Aquavit Pharmaceuticals forms Alliance Partnership with Accelrys
4. Aquavit and Green Cross Sign Strategic Collaboration MOU on IBX-001 Product Development and Commercialization in Asia
5. Jazz Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference on November 12
6. Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
7. Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
8. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
9. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
10. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
11. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):